Project Details
| Short title | XL184-313 |
|---|---|
| Acronym | COSMIC |
| Status | Active |
| Effective start/end date | 2/10/19 → 11/07/24 |
A randomized, double-blind, controled phase 3 study of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in subjects with previously untreated advanced or metastatic renal cell carcinoma of intermediate to poor risk
- Gurney, Howard (Primary Chief Investigator)
- Butala, Radhika (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
- Parshionikar, Abhijit (Clinical Trial Unit Staff)
- Rajasekharan Nair, Archana (Clinical Trial Unit Staff)
Project: Other